文献速递药物不良反应与药物警戒药物相互作用

胰岛素促泌剂与ACEI联用低血糖风险的系统评价

Risk of Hypoglycemia Associated With Concomitant Use of Insulin Secretagogues and ACE Inhibitors in Adults With Type 2 Diabetes: A Systematic Review.
PubMed 文献 · Clin Pharmacol Ther · 2024-12-13

该系统评价检索MEDLINE/PubMed和Embase至2023年7月,纳入5项评估成人2型糖尿病患者联用胰岛素促泌剂与ACEI后严重低血糖风险的研究。研究异质性阻止了荟萃分析,两项采用多种方法控制偏倚的研究未发现关联,三项提示可能关联但仅一项有统计学意义且存在严重偏倚风险。

要点

  • 高质量研究未发现胰岛素促泌剂与ACEI联用增加低血糖风险。
  • 提示关联的研究多存在未调整肾功能不全等严重偏倚。
  • 药品集和电子健康记录应考虑更新或移除该药物相互作用警示。

核心结论

  • 较高质量研究未发现胰岛素促泌剂与ACEI联用与低血糖存在关联。

研究设计与样本

  • 系统评价,检索MEDLINE/PubMed和Embase自建库至2023年7月,最终纳入5项研究。

主要发现

  • 文献检索共获得472篇论文,其中5篇符合纳入标准。
  • 两项使用多种方法处理偏倚的研究未发现低血糖与ACEI联用胰岛素促泌剂的关联。
  • 三项研究发现潜在关联,但仅一项有统计学意义,且这些研究因未调整肾功能不全存在严重或极严重偏倚风险。

临床怎么用

  • 药品集和电子健康记录应考虑更新并移除针对胰岛素促泌剂与ACEI类药物相互作用的警示。

局限性

  • 研究间异质性阻止了荟萃分析。
  • 三项提示关联的研究存在严重或极严重偏倚风险,主要因未调整肾功能不全。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Insulin secretagogues and angiotensin-converting enzyme inhibitors (ACEIs) are commonly co-prescribed for patients with type 2 diabetes (T2D). Case reports suggesting that co-administration of insulin secretagogues with ACEIs is associated with an increased risk of serious hypoglycemia have led to warnings regarding a drug-drug interaction in widely used drug compendia. However, subsequent studies have had inconsistent results. We performed a systematic review to evaluate the evidence that concomitant use of ACEIs and insulin secretagogues increases the risk of serious hypoglycemia. MEDLINE/PubMed and Embase were searched from inception to July 2023 for studies evaluating adults with T2D treated with insulin secretagogues, such as sulfonylureas or meglitinides, and exposed to an ACEI. The primary outcome was serious hypoglycemia. A literature search yielded 472 papers, of which five met the inclusion criteria. The heterogeneity of the studies precluded meta-analysis. Two studies using multiple methods to address bias found no association between hypoglycemia and concomitant use of ACEI and insulin secretagogues. Three studies found potential associations, but only one was statistically significant; these studies were at serious or critical risk of bias due to potential confounding from lack of adjustment for renal dysfunction. The higher quality studies found no association between the concomitant use of insulin secretagogues with ACEI and hypoglycemia. Drug compendia and electronic health records should consider updating and removing alerts warning of a drug-drug interaction between insulin secretagogues as a class and ACEIs.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chu PY, Edmondson EK, Flory JH, et al. Risk of Hypoglycemia Associated With Concomitant Use of Insulin Secretagogues and ACE Inhibitors in Adults With Type 2 Diabetes: A Systematic Review. Clin Pharmacol Ther. 2024. PMID: 39670464. doi:10.1002/cpt.3530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。